Overcoming mTOR resistance mutations with a new-generation mTOR inhibitorVanessa Rodrik-Outmezguine, Kevan M. Shokat, Masanori Okaniwa et al.|Nature|2016Cited by 483
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Mothaffar F. Rimawi, Antonio Llombart‐Cussac et al.|JNCI Journal of the National Cancer Institute|2019Cited by 168